Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Scarpi

Showing results (51-60 of 215) with videos related to

Pageof 22
Sort By:
International Journal of Molecular Sciences|September 9, 2014
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimenNicola Silvestris, Giovanni Simone, Giulia Partipilo, et al.
Frontiers in Oncology|October 19, 2020
Plasma <i>AR</i> Copy Number Changes and Outcome to Abiraterone and EnzalutamideGiorgia Gurioli, Vincenza Conteduca, Cristian Lolli, et al.
Journal of Oncology|May 22, 2019
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?Giuseppe Bronte, Andrea Rocca, Sara Ravaioli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 12, 2014
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II studyGiovanni Paganelli, Maddalena Sansovini, Alice Ambrosetti, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 9, 2010
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individualsDaniele Calistri, Claudia Rengucci, Andrea Casadei Gardini, et al.
Cancer Biology & Therapy|July 1, 2015
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapyAnita Mangia, Lucia Caldarola, Stefania Dell'Endice, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 25, 2012
Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical careMarco Maltoni, Guido Miccinesi, Piero Morino, et al.
Frontiers in Oncology|September 20, 2021
Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer PatientsConcetta Saponaro, Emanuela Scarpi, Margherita Sonnessa, et al.
Plos One|December 20, 2016
Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast CancerCristiano Ferrario, Ivan Strepponi, Khashayar Esfahani, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2013
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumoursStefano Severi, Oriana Nanni, Lisa Bodei, et al.
Pageof 22

Showing results (51-60 of 215) with videos related to

Sort By:
Pageof 22
International Journal of Molecular Sciences|September 9, 2014
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimenNicola Silvestris, Giovanni Simone, Giulia Partipilo, et al.
Frontiers in Oncology|October 19, 2020
Plasma <i>AR</i> Copy Number Changes and Outcome to Abiraterone and EnzalutamideGiorgia Gurioli, Vincenza Conteduca, Cristian Lolli, et al.
Journal of Oncology|May 22, 2019
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?Giuseppe Bronte, Andrea Rocca, Sara Ravaioli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 12, 2014
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II studyGiovanni Paganelli, Maddalena Sansovini, Alice Ambrosetti, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 9, 2010
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individualsDaniele Calistri, Claudia Rengucci, Andrea Casadei Gardini, et al.
Cancer Biology & Therapy|July 1, 2015
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapyAnita Mangia, Lucia Caldarola, Stefania Dell'Endice, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 25, 2012
Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical careMarco Maltoni, Guido Miccinesi, Piero Morino, et al.
Frontiers in Oncology|September 20, 2021
Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer PatientsConcetta Saponaro, Emanuela Scarpi, Margherita Sonnessa, et al.
Plos One|December 20, 2016
Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast CancerCristiano Ferrario, Ivan Strepponi, Khashayar Esfahani, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2013
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumoursStefano Severi, Oriana Nanni, Lisa Bodei, et al.
Pageof 22